RecruitingPhase 2NCT04637620

NMDA Modulation in Major Depressive Disorder

Sponsor

China Medical University Hospital

Enrollment

90 participants

Start Date

Jun 1, 2017

Study Type

INTERVENTIONAL

Conditions

Major Depressive Disorder

Summary

Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria4

Have a DSM-5 (American Psychiatric Association) diagnosis of MDD
item Hamilton Rating Scale for Depression total score ≥ 18
Free of antidepressant drugs for at least 2 weeks
Agree to participate in the study and provide informed consent

Exclusion Criteria10

Current substance abuse or history of substance dependence in the past 6 months
History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
Bipolar depression, schizophrenia or other psychotic disorder
Moderate-severe suicidal risks
Severe cognitive impairment
Initiating or stopping formal psychotherapy within six weeks prior to enrollment
A history of severe adverse reaction to SSRIs
A treatment-resistant history (that is, they have failed to respond to two or more different classes of antidepressants with adequate dosage and treatment duration
A history of previously received electroconvulsive therapy
Inability to follow protocol